Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about Sumitomo Corporation aggregated by PharmaCompass.com.

    Client Virtual Booth

    SUMITOMO CORPORATION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Sumitomo Corporation
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    Yubinbango 100-8601 Otemachi, Chiyoda-ku, Tokyo chome No. 3 No. 2 Otemachi Place East Tower
    Telephone
    Telephone
    03-6285-5000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sumitomocorp.com/ja/jp
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Setsuro Tech gets access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan
    Setsuro Tech gets access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan

    https://www.biospectrumasia.com/news/98/17737/setsuro-tech-gets-access-to-ers-genomics-crispr-cas9-patent-portfolio-for-japan.html

    BIOSPECTRUMASIA
    10 Mar 2021
    Share Share
    Sumitomo Chemical accelerates next-gen biz utilizing synthetic biology
    Sumitomo Chemical accelerates next-gen biz utilizing synthetic biology

    https://www.biospectrumasia.com/news/28/17132/sumitomo-chemical-accelerates-next-gen-biz-utilizing-synthetic-biology.html

    BIOSPECTRUMASIA
    16 Nov 2020
    Share Share
    Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial
    Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial

    https://endpts.com/sumitomo-subsidiary-flashes-new-way-of-treating-schizophrenia-in-phase-ii-trial/

    Jason Mast COM
    16 Apr 2020
    Share Share
    Poxel, Sumitomo Pharma Announce +Ve Phase 3 Results from TIMES 2 Trial
    Poxel, Sumitomo Pharma Announce +Ve Phase 3 Results from TIMES 2 Trial

    https://www.businesswire.com/news/home/20191219005696/en

    BUSINESSWIRE
    20 Dec 2019
    Share Share
    Rentschler Biopharma reveals push for expanding operation in Japan
    Rentschler Biopharma reveals push for expanding operation in Japan

    https://www.manufacturingchemist.com/news/article_page/Rentschler_Biopharma_reveals_push_for_expanding_operation_in_Japan/158792

    Murielle Gonzalez MANUFACTURING
    05 Oct 2019
    Share Share
    Sumitomo Corporation Acquires Ownership Of Paris Distributor SACI-CFPA; Expands Global Footprint In Personal Care Market
    Sumitomo Corporation Acquires Ownership Of Paris Distributor SACI-CFPA; Expands Global Footprint In Personal Care Market

    https://www.prnewswire.com/news-releases/sumitomo-corporation-acquires-ownership-of-paris-distributor-saci-cfpa-expands-global-footprint-in-personal-care-market-300821488.html

    PR NEWSWIRE
    01 Apr 2019
    Share Share
    Sumitomo (SHI) Demag syncs ejector with medical mould movement
    Sumitomo (SHI) Demag syncs ejector with medical mould movement

    https://www.manufacturingchemist.com/news/article_page/Sumitomo_SHI_Demag_syncs_ejector_with_medical_mould_movement/149641

    MANUFACTURING CHEMIST
    29 Nov 2018
    Share Share
    Japan permits Toray’s Additional Indication of Pruritus Treatment Drug
    Japan permits Toray’s Additional Indication of Pruritus Treatment Drug

    http://www.biospectrumasia.com/biospectrum/news/221350/japan-permits-toray-s-additional-indication-pruritus-treatment-drug

    Biospectrum Bureau BIOSPECTRUM ASIA
    22 May 2015
    Share Share
    Takeda, Orexigen end CV study for obesity drug Contrave
    Takeda, Orexigen end CV study for obesity drug Contrave

    http://www.fiercepharmaasia.com/story/takeda-orexigen-end-cv-study-obesity-drug-contrave/2015-05-12

    Ej Lane FIERCE PHARMA ASIA
    13 May 2015
    Share Share
    Sumitomo Dainippon says Latuda for schizophrenia in Japan misses PhIII aims
    Sumitomo Dainippon says Latuda for schizophrenia in Japan misses PhIII aims

    http://www.fiercepharmaasia.com/story/sumitomo-dainippon-says-latuda-schizophrenia-japan-misses-phiii-aims/2015-04-27

    Ej Lane FIERCE PHARMA ASIA
    27 Apr 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search